Nebenwirkungen · Rezzayo
REZZAYO 200 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 5
HOS-150146 · Präparat HOS-100248
The following table includes adverse reactions from 173 subjects that received rezafungin 400/200 mg listed by system organ class (SOC) and MedDRA preferred terms with frequency corresponding to very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000), very rare (< 1/10 000) and from spontaneous reports with frequency not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T11:20:00Z · SHA-256 b1f585b2518251fa4f69ea1c54f598fabac01013c076f0c0cd2c4c84c64ceb88 · Passage c57ec5573271b5e51866f1ce71ab0e2f85005cfb7fd37380595c1bf9831c983f · Zeichen 415–948 im Abschnitt